Image
Back to top
Prof Brian Kirby
Consultant Dermatologist
Professor Brian Kirby is Consultant Dermatologist at St Vincent’s University Hospital, Dublin, Ireland, and Full Clinical Professor at University College Dublin, Ireland.
Professor Kirby’s clinical and research interests include psoriasis and hidradenitis suppurativa. He is co-Chair of the Dublin Hidradenitis Suppurativa Research Group and a Principal Investigator at the Charles Institute of Dermatology at University College Dublin.
Professor Kirby is also a former member of the steering committee of British Association of Dermatologists Biologics and Immunomodulatory Register (BADBIR), a member of the International Psoriasis Council (IPC), a member of the scientific committee of the European Hidradenitis Suppurativa Foundation (EHSF) and Chairperson of the Clinical Advisory Group of Dermatology at the Royal College of Physicians of Ireland.
He has authored or co-authored more than 250 publications, the majority of which are on psoriasis and hidradenitis suppurativa. Additionally, he is Associate Editor of the British Journal of Dermatology and Dermatology.
0 resources
Video42:07 min
Prof. Farida Benhadou discusses the practicalities and potential challenges of implementing multidisciplinary care for HS management
EU-DA-2400344
Video1:13:07 min
Prof. Falk Bechara covers the different surgical options for HS, and experienced nurses from his team discuss the importance of wound care
EU-DC-2400105
Video1:19:16 min
Prof. Tzellos, Dr Martorell, Dr McGrath and Prof. Jemec detail HS treatment options, the role of imaging and the HCP-patient relationship
EU-BK-2400245
Video1:11:49 min
Prof. Christos Zouboulis and Dr Axel Villani kick-off the webinar series by explaining the fundamentals of the HS disease story and pathophysiology
EU-DC-2400107
Video35 minutes watch
Accompany Dr William Tillett and Dr Fabian Proft as they explore the approaches and challenges of managing D2T patients with PsA.
EU-DA-2400672
Infographic2 minutes read
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
EU-DA-2400673